2025 Letter reminders:
* PD-L1 Upregulation: 16/21 (76%) of patients showed a significant increase in PD-L1 expression on CTCs within 30-90 days after starting leronlimab, regardless of dose. This suggests that the tumor microenvironment was turned from “cold” to “hot” (from being protected against host immune invasion to being under host immune attack). Even more remarkably, this shift from “cold” to “hot” occurred in 15/17 (88%) patients who received weekly leronlimab doses of 525 mg or higher. Turning “cold” tumors “hot” means that far more patients with TNBC (and potentially other solid tumors) may become eligible for a class of drugs known as anti-PD-1/anti-PD-L1 treatments and collectively referred to as ICIs."
(Yep, current mCRC 700mg data should be a world-wide showstopper)
* The Company has also prepared a case report of a patient with mTNBC whose cancer had spread to both brain and lungs, but who is alive today without evidence of disease, almost 5 years after receiving fourth-line treatment with leronlimab plus atezolizumab. That manuscript will be submitted for peer review shortly."
Keytruda:
*Past mTNBC trial
*2025 Compassionate patient
Tecentriq:
*Past mTNBC trial
* Mrs. Peterson 8 yrs LL combo
Atezolizumab:
*Past mTNBC trial
Initial 2026 mCRC trial data pointing towards Leronlimab causing paradim shifts.
Shifts --- yes, plural.
* PD-L1 Upregulation: 16/21 (76%) of patients showed a significant increase in PD-L1 expression on CTCs within 30-90 days after starting leronlimab, regardless of dose. This suggests that the tumor microenvironment was turned from “cold” to “hot” (from being protected against host immune invasion to being under host immune attack). Even more remarkably, this shift from “cold” to “hot” occurred in 15/17 (88%) patients who received weekly leronlimab doses of 525 mg or higher. Turning “cold” tumors “hot” means that far more patients with TNBC (and potentially other solid tumors) may become eligible for a class of drugs known as anti-PD-1/anti-PD-L1 treatments and collectively referred to as ICIs."
(Yep, current mCRC 700mg data should be a world-wide showstopper)
* The Company has also prepared a case report of a patient with mTNBC whose cancer had spread to both brain and lungs, but who is alive today without evidence of disease, almost 5 years after receiving fourth-line treatment with leronlimab plus atezolizumab. That manuscript will be submitted for peer review shortly."
Keytruda:
*Past mTNBC trial
*2025 Compassionate patient
Tecentriq:
*Past mTNBC trial
* Mrs. Peterson 8 yrs LL combo
Atezolizumab:
*Past mTNBC trial
Initial 2026 mCRC trial data pointing towards Leronlimab causing paradim shifts.
Shifts --- yes, plural.
5
